Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003966 · ClinicalTrials.gov registry record · Phase 2
Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT00003966 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 151 participants.
The verdict
NCT00003966, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
RATIONALE: Giving defibrotide may be an effective treatment for liver damage that may result following peripheral stem cell transplantation. PURPOSE: This randomized phase II trial is studying defibrotide to see how well it works in treating patients with severe liver disease after undergoing peripheral stem cell transplantation.
Interventions
- DRUG defibrotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2000-04 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003966
The ClinicalTrials.gov registry entry for NCT00003966 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which defibrotide is the first listed.
NCT00003966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003966 about?
NCT00003966 is a clinical study titled "Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation". RATIONALE: Giving defibrotide may be an effective treatment for liver damage that may result following peripheral stem cell transplantation. PURPOSE: This randomized phase II trial is studying defibrotide to see how well it works in treating patients with severe liver disease after undergoing perip...
What is the current status of trial NCT00003966?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2000-04. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00003966?
The interventions under investigation include: defibrotide (DRUG).
Who is sponsoring clinical trial NCT00003966?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.